The trial met the primary endpoint of improved leukemia-free survival (LFS) and HDC was approved by the European Medicines Agency as maintenance therapy in AML in conjunction with LD-IL-2 for adult patients in first CR (CR1). The gene discussed is IL2; the disease is acute myeloid leukemia.